ES2421453T3 - Derivados de tiofenocarboxamida como ligandos del receptor EP4 - Google Patents

Derivados de tiofenocarboxamida como ligandos del receptor EP4

Info

Publication number
ES2421453T3
ES2421453T3 ES07815782T ES07815782T ES2421453T3 ES 2421453 T3 ES2421453 T3 ES 2421453T3 ES 07815782 T ES07815782 T ES 07815782T ES 07815782 T ES07815782 T ES 07815782T ES 2421453 T3 ES2421453 T3 ES 2421453T3
Authority
ES
Spain
Prior art keywords
formula
group
receptor ligands
thiophenecarboxamide derivatives
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES07815782T
Other languages
English (en)
Spanish (es)
Inventor
Marc Blouin
Jason Burch
Han Yongxin
Christophe Mellon
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Canada Inc
Original Assignee
Merck Canada Inc
Merck Frosst Canada Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Canada Inc, Merck Frosst Canada Ltd filed Critical Merck Canada Inc
Application granted granted Critical
Publication of ES2421453T3 publication Critical patent/ES2421453T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
ES07815782T 2006-08-11 2007-08-10 Derivados de tiofenocarboxamida como ligandos del receptor EP4 Active ES2421453T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US83725206P 2006-08-11 2006-08-11
PCT/CA2007/001404 WO2008017164A1 (en) 2006-08-11 2007-08-10 Thiophenecarboxamide derivatives as ep4 receptor ligands

Publications (1)

Publication Number Publication Date
ES2421453T3 true ES2421453T3 (es) 2013-09-02

Family

ID=39032586

Family Applications (1)

Application Number Title Priority Date Filing Date
ES07815782T Active ES2421453T3 (es) 2006-08-11 2007-08-10 Derivados de tiofenocarboxamida como ligandos del receptor EP4

Country Status (8)

Country Link
US (1) US8969394B2 (enExample)
EP (1) EP2054401B1 (enExample)
JP (1) JP5259592B2 (enExample)
CN (1) CN101541778B (enExample)
AU (1) AU2007283404B2 (enExample)
CA (1) CA2660133C (enExample)
ES (1) ES2421453T3 (enExample)
WO (1) WO2008017164A1 (enExample)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110028463A1 (en) * 2007-07-03 2011-02-03 Astellas Pharma Inc. Amide compounds
CA2694347A1 (en) * 2007-08-09 2009-02-12 Merck Sharp & Dohme Corp. Process for making thiophene carboxamide derivative
SI2565191T1 (sl) * 2008-05-14 2014-12-31 Astellas Pharma Inc. Derivati 4-(indol-7-ilkarbonilaminometil)cikloheksan karboksilne kisline kot EP4 receptorski antagonisti, uporabni za zdravljenje kronične ledvične odpovedi ali diabetične nefropatije
EP2320906B1 (en) * 2008-08-14 2016-02-24 Beta Pharma Canada Inc. Heterocyclic amide derivatives as ep4 receptor antagonists
JP2013508282A (ja) 2009-10-14 2013-03-07 ジェンムス ファーマ インコーポレイティド ウイルス感染のための併用療法処置
MX341482B (es) * 2010-02-22 2016-08-22 Raqualia Pharma Inc Antagonistas del receptor ep4 y su uso en el tratamiento de enfermedades mediadas por la il-23.
PH12013500467A1 (en) 2010-09-21 2013-04-29 Eisai R&D Man Co Ltd Pharmaceutical composition
CA2820109C (en) 2010-12-10 2018-01-09 Rottapharm S.P.A. Pyridine amide derivatives as ep4 receptor antagonists
UA115576C2 (uk) 2012-12-06 2017-11-27 Байєр Фарма Акцієнгезелльшафт Похідні бензимідазолу як антагоністи ер4
US10391086B2 (en) 2013-03-19 2019-08-27 Askat Inc. Use of EP4 receptor antagonists in the treatment of cartilage disease
KR102556734B1 (ko) 2013-03-19 2023-07-18 에스크엣 인크. 연골질환 치료에서의 ep4 수용체 길항제의 용도
PT3009426T (pt) 2013-06-12 2018-06-08 Kaken Pharma Co Ltd Derivado de 4-alquinilimidazole e medicamento compreendendo o mesmo como ingrediente ativo
EP3492106B1 (en) 2013-08-09 2021-02-17 Ardelyx, Inc. Compounds and methods for inhibiting phosphate transport
TW201607943A (zh) 2013-12-19 2016-03-01 拜耳製藥公司 作為ｅｐ４配體之新穎苯并咪唑衍生物
TW201623277A (zh) 2014-03-26 2016-07-01 安斯泰來製藥股份有限公司 醯胺化合物
US20170182003A1 (en) * 2014-05-23 2017-06-29 Eisai R&D Management Co., Ltd. Combination therapies for the treatment of cancer
US9926262B2 (en) * 2014-06-06 2018-03-27 Allergan, Inc. EP4 agonists as therapeutic compounds
CN105037186A (zh) * 2015-06-17 2015-11-11 苏州敬业医药化工有限公司 一种氨甲苯酸的制备方法
CR20180323A (es) 2015-11-20 2018-08-06 Idorsia Pharmaceuticals Ltd Derivados de indol n-sustituídos como moduladores de los receptores de pge2
WO2018162562A1 (en) 2017-03-10 2018-09-13 Bayer Pharma Aktiengesellschaft Use of an ep4 antagonist for the treatment of inflammatory pain
AR111941A1 (es) 2017-05-18 2019-09-04 Idorsia Pharmaceuticals Ltd Derivados de pirimidina como moduladores del receptor de pge2
MX388257B (es) 2017-05-18 2025-03-19 Idorsia Pharmaceuticals Ltd Derivados de pirimidina como moduladores del receptor de pge2.
EP3625223B1 (en) 2017-05-18 2021-08-11 Idorsia Pharmaceuticals Ltd Pyrimidine derivatives
US20200069686A1 (en) 2017-05-18 2020-03-05 Idorsia Pharmaceuticals Ltd N-substituted indole derivatives
JP7093791B2 (ja) 2017-05-18 2022-06-30 イドーシア ファーマシューティカルズ リミテッド Ｐｇｅ２レセプター調節剤としてのベンゾフラン及びベンゾチオフェン誘導体
WO2019038156A1 (en) 2017-08-22 2019-02-28 Bayer Pharma Aktiengesellschaft USE OF AN EP4 ANTAGONIST FOR THE TREATMENT OF ARTHRITIS
US10202415B1 (en) 2017-10-19 2019-02-12 King Saud University Method of synthesizing of 3-oxolupenal nanoparticles
EP3972599B1 (en) 2019-05-21 2025-10-22 Ardelyx, Inc. Combination for lowering serum phosphate in a patient
CN112552200B (zh) * 2019-09-10 2024-03-12 烟台药物研究所 一种光学纯4-(1-氨基)乙基苯甲酸酯及其盐的制备方法
US20240002388A1 (en) * 2020-08-18 2024-01-04 Hutchison Medipharma Limited Pyrimidinone compounds and uses thereof
EP4245301A4 (en) 2020-11-13 2024-08-21 ONO Pharmaceutical Co., Ltd. TREATMENT OF CANCER BY COMBINED USE OF AN EP4 ANTAGONIST AND AN IMMUNE CHECKPOINT INHIBITOR

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5962490A (en) * 1987-09-25 1999-10-05 Texas Biotechnology Corporation Thienyl-, furyl- and pyrrolyl-sulfonamides and derivatives thereof that modulate the activity of endothelin
EP0752421B1 (en) 1995-07-07 2005-10-12 AstraZeneca AB Ortho-substituted aromatic compounds, containing three (het)aryl moieties, their preparation and their use as prostaglandin E2-(PGE2)-antagonists
BR0116850A (pt) * 2001-01-31 2004-02-25 Pfizer Prod Inc Derivados de amida de ácido tiazolil-, oxazolil-, pirrolil- e imidazolil- úteis como inibidores de isoenzimas de pde4
WO2004099127A1 (en) 2003-05-07 2004-11-18 Novo Nordisk A/S Novel compounds as kinase inhibitors
RS20060143A (sr) * 2003-09-03 2008-06-05 Pfizer Inc., Jedinjenja fenil ili piridil amida kao antagonisti prostaglandina e2
GB0324269D0 (en) * 2003-10-16 2003-11-19 Pharmagene Lab Ltd EP4 receptor antagonists
CA2563356A1 (en) * 2004-04-20 2005-11-03 Pfizer Products Inc. Combinations comprising alpha-2-delta ligands and ep4 receptor antagonists
JP4054368B2 (ja) * 2004-05-04 2008-02-27 ファイザー株式会社 置換メチルアリール又はヘテロアリールアミド化合物
CN1950334A (zh) * 2004-05-04 2007-04-18 辉瑞有限公司 邻位取代的芳基或杂芳基酰胺化合物
WO2005116010A1 (en) * 2004-05-26 2005-12-08 Merck Frosst Canada Ltd. Ep4 receptor agonist, compositions and methods thereof

Also Published As

Publication number Publication date
CN101541778B (zh) 2014-10-08
US20090247596A1 (en) 2009-10-01
WO2008017164A1 (en) 2008-02-14
CA2660133A1 (en) 2008-02-14
AU2007283404A1 (en) 2008-02-14
JP5259592B2 (ja) 2013-08-07
JP2010500293A (ja) 2010-01-07
CA2660133C (en) 2015-10-27
EP2054401A1 (en) 2009-05-06
EP2054401B1 (en) 2013-05-01
AU2007283404B2 (en) 2013-04-18
CN101541778A (zh) 2009-09-23
EP2054401A4 (en) 2010-10-13
US8969394B2 (en) 2015-03-03

Similar Documents

Publication Publication Date Title
ES2421453T3 (es) Derivados de tiofenocarboxamida como ligandos del receptor EP4
ECSP12012292A (es) Ciertas amino-piridazinas, composicioines de las mismas y métodos de uso de los mismos
AR086828A1 (es) Compuestos heterociclicos fusionados como moduladores del canal ionico
AR087328A1 (es) Derivados de imidazo[1,2-b]piridazina e imidazo[4,5-b]piridina como inhibidores de jak
AR098912A1 (es) Inhibidores de syk
ES2618003T3 (es) Compuestos tricíclicos sustituidos como inhibidores de FGFR
ECSP12012293A (es) Ciertas amino-pirimidinas, composicioines de las mismas y métodos para el uso de los mismos
UY35641A (es) PROCEDIMIENTO DE SÍNTESIS PARA PREPARAR ANÁLOGOS MACROCÍCLICOS C1-CETO DE HALICONDRINA B, E INTERMEDIARIOS ÚTILES INCLUYENDO INTERMEDIARIOS CONTENIENDO GRUPOS ?SO2-(p-TOLILO)
AR091786A1 (es) Inhibidores de la produccion de leucotrienos
CO6220972A2 (es) Derivados de 6-amino dihidropurin -8-ona utiles como agentes terapeuticos y/o preventivos para el tratamiento de enfermedades alergicas, virales o cancer
AR063318A1 (es) Pirazoliltienopiridinas terapeuticas
ES2626801T3 (es) Compuestos de triazolopiridina como inhibidores de pde10a
CO6440533A2 (es) Nucleósidos espiro oxetánicos uracílicos
AR097079A1 (es) SALES DE DERIVADOS DE 2-AMINO-1-HIDROXIETIL-8-HIDROXIQUINOLIN-2(1H)-ONA QUE TIENEN ACTIVIDAD ANTAGONISTA DE RECEPTORES MUSCARÍNICOS ASÍ COMO ACTIVIDAD AGONISTA DEL RECEPTOR b2 ADRENÉRGICO
SV2011003997A (es) Pirimidinas fusionadas
CO2017000980A2 (es) Compuestos derivados de imidazo[1,2-b]piridazin-2-carboxamida e imidazo[1,2- b]piridazin-2-ilmetanona activos como inhibidores selectivos de la fosfodiesterasa 4a (pde4a)
AR089781A1 (es) Fluorometil-5,6-dihidro-4h-[1,3]oxazinas
AR089568A1 (es) Compuestos heterociclicos y sus metodos de usos
EA201591545A1 (ru) C-3 алкил- и алкенил-модифицированные производные бетулиновой кислоты
PE20141352A1 (es) Fenil-3-aza-biciclo[3,1,0]hex-3-il-metanonas y su uso como medicamento
AR090474A1 (es) Compuestos de tetrahidropirrolotiazina
AR075367A1 (es) Inhibidores de glucosilceramida sintasa
PE20211769A1 (es) Compuestos heteroaromaticos como inhibidores de vanina
MX366820B (es) Moduladores de gpr120 del acido biciclo[2.2.2].
PE20210478A1 (es) Compuestos heteroaromaticos como inhibidores de vanina